These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 24631288

  • 21. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, Wang YY.
    BMC Cancer; 2016 Jul 18; 16():491. PubMed ID: 27431492
    [Abstract] [Full Text] [Related]

  • 22. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
    Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B.
    Cancer Res; 2005 Aug 15; 65(16):7096-101. PubMed ID: 16103058
    [Abstract] [Full Text] [Related]

  • 23. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT.
    Lung Cancer; 2013 Nov 15; 82(2):305-12. PubMed ID: 24055492
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
    Song J, Zhong R, Huang H, Zhang Z, Ding D, Yan H, Sun E, Jia X.
    Nutr Cancer; 2014 Nov 15; 66(4):682-9. PubMed ID: 24738693
    [Abstract] [Full Text] [Related]

  • 29. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    J Thorac Oncol; 2015 Jan 01; 10(1):93-101. PubMed ID: 25384171
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 01; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 33. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
    Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S.
    Oncogene; 2013 Sep 12; 32(37):4427-35. PubMed ID: 23045273
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.
    Cancer Res; 2007 Nov 01; 67(21):10417-27. PubMed ID: 17974985
    [Abstract] [Full Text] [Related]

  • 37. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
    Mol Cancer Ther; 2012 Jan 01; 11(1):204-13. PubMed ID: 22075159
    [Abstract] [Full Text] [Related]

  • 38. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M, Takahashi T, Yamamoto N, Koh Y.
    J Thorac Oncol; 2013 Mar 01; 8(3):259-69. PubMed ID: 23334091
    [Abstract] [Full Text] [Related]

  • 39. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 40. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 26; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.